Medscape Conference Coverage, based on selected sessions at the:

EuroPCR 2006 -- The Paris Course on Revascularization

May 16 - 19, 2006; Paris, France

This activity is not sanctioned by, nor a part of, EuroPCR 2006.

Interventional Corner

The European Paris Course on Revascularization (EuroPCR) is well recognized for its brilliant integration of live case demonstrations coupled with the advancement of education in the field of percutaneous interventions. The goals of the meeting are simple: "To contribute to the advancement of education and information on existing and new technologies in the fields of percutaneous interventions (coronary, peripheral and non-coronary cardiac diseases), cardiac and vascular invasive and non-invasive imaging."

These simple objectives were achieved with ease by the Course Directors Prof. Marco and Prof. Fajadet, and with the help of a very solid international faculty. This year, during the opening ceremony in front of an audience of more than 10,000 attendees, Prof. Marco in conjunction with Prof. Tandera, President of the European Society of Cardiology, announced the merger between EuroPCR, the European Society of Cardiology, the Interventional Cardiology Working Group, and Europa Association. The newly formed association, the European Society of Percutaneous Cardiovascular Interventions (EAPCI), will be an independent branch of the European Society of Cardiology. EuroPCR will be the official meeting of the EAPCI and its official journal will be named EuroIntervention. Furthermore, and in concordance with this new entity, next year's meeting will no longer be held in Paris, France, but will move to Barcelona, Spain.

Seventeen years after its humble origins at the Institute Pasteur in Toulouse, France, and 6 years after being introduced at the Palais des Congrès in Paris, the meeting leaves for new grounds. There is no doubt that we will miss Paris, but in this ever-changing world of interventional cardiology, we are sure the collaborative efforts will lead to further improvement and important growth.

Conference Review
Late-Breaking Trials

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the EuroPCR 2006. These materials and the related activity are not sanctioned by the EuroPCR 2006 or the commercial supporter of the conference, and do not constitute an official part of that conference.